MVP Act
- Bill Number
- S. 1637
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-07: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-03-11T14:45:59Z
AI-Generated Summary
Purpose
The "Medicaid VBPs for Patients Act" (MVP Act) aims to integrate value-based purchasing (VBP) arrangements into the Medicaid program. VBP arrangements tie drug payments to patient health outcomes (e.g., refunds if outcomes are not met), promoting efficient use of taxpayer funds while ensuring broad access to innovative drugs. The bill codifies these arrangements, updates pricing rules, and provides safeguards to encourage their adoption without legal risks.
Key Provisions
- Codification of VBP in Medicaid Pricing: Allows drug manufacturers to report multiple "best price" points (the lowest price offered) for a single drug under VBP arrangements, but only if the arrangement is offered equally to all states. This treats VBP as potentially a "bundled sale" (a package deal including services or outcomes).
- Updates to Average Manufacturer Price (AMP) Calculation: Includes in AMP any refunds, rebates, or payment reductions triggered by poor patient outcomes in VBP deals. For drugs paid in installments under VBP, the full arrangement price is counted as paid upfront. Applies to various drug types, including those not typically sold at retail pharmacies (e.g., infusions or implants).
- Definition of VBP Arrangement: References existing federal regulations (42 CFR 447.502) defining VBP as payment models linking reimbursement to clinical results or quality measures.
- Medicare Alignment: Excludes certain VBP-related refunds from Medicare's average sales price (ASP) calculations if the manufacturer reports multiple best prices under Medicaid rules, ensuring consistency between programs.
- Guidance for Inpatient Drugs: Requires the Secretary of Health and Human Services (HHS) to issue guidance within 180 days on using VBP for inpatient hospital drugs reimbursed separately (not bundled into hospital payments). Includes options for multi-state agreements to handle out-of-state patient care.
- Anti-Kickback Exception: Adds a safe harbor under the Anti-Kickback Statute, exempting VBP-related payments (e.g., outcome-based refunds to states) from being treated as illegal inducements. HHS Inspector General must implement via rulemaking within 180 days.
- GAO Study and Report: Mandates a Government Accountability Office (GAO) study on VBP's effects on drug access, patient outcomes, costs, and program compliance. The report, due by June 30, 2029, will cover impacts on therapies (e.g., gene therapies for rare diseases), disparities, rebates, and state savings.
Significant Changes to Existing Law
- Medicaid Drug Rebate Program (Section 1927): Expands flexibility in best price reporting to accommodate VBP's variable pricing, previously limited to a single lowest price per drug form/strength. Introduces outcome-based elements into AMP, which previously focused more on standard discounts.
- Medicare Part B Drug Pricing (Section 1847A): Aligns ASP exclusions with Medicaid's VBP rules, preventing double-counting of refunds and simplifying cross-program reporting.
- Anti-Kickback Protections (Section 1128B): Creates a new explicit exception for VBP remunerations, building on existing safe harbors but tailored to outcome-linked payments in Medicaid.
- Implementation Timeline: Requires HHS rulemaking within 180 days for key changes, faster than typical regulatory processes, to enable quick adoption.
Potential Impacts
- Government Agencies: HHS and Centers for Medicare & Medicaid Services (CMS) will need to develop rules, guidance, and oversight, potentially increasing administrative workload but enabling cost controls. States gain tools for negotiating better drug deals, possibly reducing Medicaid expenditures. GAO's study could inform future policy adjustments.
- Citizens and Patients: Improves access to effective drugs by requiring VBP deals to be available to all states, reducing disparities (e.g., for low-income or rural enrollees). Ties payments to outcomes, potentially leading to better health results and lower out-of-pocket costs, though short-term access to new therapies (like rare disease treatments) might vary.
- International Relations: No direct impacts, as the bill focuses on domestic U.S. health programs.
- Broader Health System: Encourages shift from volume-based (pay-per-drug) to value-based care, potentially lowering overall costs for federal programs like Medicaid and Medicare, but could increase complexity in pricing for non-participating states.
Main Stakeholders Affected
- State Medicaid Agencies: Primary beneficiaries, gaining negotiation power and multi-state collaboration options; must decide on VBP participation.
- Drug Manufacturers: Face requirements to offer VBP uniformly but gain pricing flexibility and legal protections, encouraging innovation in outcome-tied models.
- Patients and Enrollees: Medicaid beneficiaries (over 70 million low-income Americans) could see improved drug access and outcomes; vulnerable groups (e.g., those with chronic or rare conditions) may benefit most.
- Healthcare Providers and Hospitals: Inpatient settings can use VBP for separately reimbursed drugs, simplifying payments but requiring outcome tracking.
- Federal Government (HHS, CMS, GAO): Responsible for implementation, enforcement, and evaluation; impacts budget through potential rebate savings.
- Other Programs: Affects 340B drug discount program (for safety-net providers) and Medicare Part B, requiring compliance adjustments.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens VBP by resolving ambiguities in pricing laws (e.g., best price, AMP) and providing Anti-Kickback immunity, reducing litigation risks for manufacturers and states. References existing regulations for definitions, ensuring continuity without overhauling frameworks.
- Constitutional: No apparent challenges; aligns with Congress's spending power under the General Welfare Clause for federal-state health programs.
- Political: Bipartisan sponsorship (Senators Mullin, Hassan, Scott) signals broad support for cost-control measures in Medicaid, a major federal expense ($600+ billion annually). Promotes equity by mandating uniform VBP access, but GAO study could highlight implementation gaps, influencing future reforms.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Hassan, Margaret Wood [D-NH], Sen. Scott, Tim [R-SC]
Recent Actions
- 2025-05-07: Read twice and referred to the Committee on Finance.
- 2025-05-07: Introduced in Senate
Bill Versions
- Medicaid VBPs for Patients Act — issued 2025-05-07 — PDF (10 pages)